Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Schwaz – page 22

373 clinical trials in Schwaz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Schwaz at a glance
373
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

373 trials in Schwaz

Open in trial search

Breast cancer+7

Not recruiting

Study of sacituzumab govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:GBG Forschungs GmbH

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Fallopian tube cancer+2

Not recruiting

Study of Nemvaleukin Alfa and Pembrolizumab for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nemvaleukin Alfa
  • Sponsor:Mural Oncology Inc.

Plasma cell myeloma

Not recruiting

Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Pfizer Inc.

Study of Pembrolizumab and Lenvatinib for Patients with Resectable Non-Small-Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Medizinische Universitaet Innsbruck

Breast cancer

Not recruiting

Study of Camizestrant and CDK4/6 Inhibitor for Patients with Advanced Breast Cancer with ESR1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Study of iptacopan effectiveness in achieving remission in patients with active ANCA-associated vasculitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of Eplontersen for Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Prostate cancer

Not recruiting

Study of Apalutamide for Patients with High-Risk Prostate Cancer After Prostate Removal

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Universitaet Muenster

Anaesthesia

Not recruiting

Study on the Effects of Ropivacaine and Lidocaine in Patients Receiving Cardiac Device Implants

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine Hydrochloride
  • Sponsor:Medizinische Universitaet Innsbruck

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Schwaz

What the registry says about research in the country

01 Advanced Breast Cancer Research

Clinical trials focusing on HER2-positive breast cancer treatment, evaluating novel combination therapies with tucatinib, pertuzumab, and trastuzumab for patients with advanced or metastatic disease.

  • Treatment Evaluation
  • Disease Progression Assessment
  • Combination Therapy

Research aims to measure progression-free survival using established evaluation criteria.

02 Targeted Therapy Studies

Investigation of elacestrant plus everolimus in treating patients with specific breast cancer subtypes, particularly focusing on those with estrogen receptor-positive and HER2-negative disease.

  • ESR1-Mutation Research
  • Endocrine Therapy
  • CDK4/6 Inhibitor Studies

Double-blind studies examining effectiveness in patients who have progressed after previous treatments.

03 Precision Medicine Applications

Advanced research incorporating biomarker-driven approaches in breast cancer treatment, with specific focus on hormone receptor status and genetic mutations.

  • Biomarker Analysis
  • Treatment Resistance
  • Personalized Medicine

Studies utilize imaging review committees to ensure accurate assessment of treatment outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.